NYSE$PBH
Prestige Consumer Healthcare Inc · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
Prestige Consumer's Q2 2025 financial results exceeded expectations, driven by strong international growth and disciplined capital deployment.
Prestige Consumer Healthcare reported Q2 2025 revenue of $283.8 million, a slight decrease of 0.9% year-over-year, but ahead of expectations. Diluted EPS increased by 2% to $1.09. The company reaffirmed its full-year fiscal 2025 revenue, earnings, and cash flow outlook.
- Q2 revenue reached $283.8 million, surpassing the company's outlook.
- Diluted EPS for Q2 was $1.09, a 2% increase compared to the previous year.
- Net cash from operating activities for the first six months was approximately $125 million, up approximately 13%.
- The company reduced debt by $75 million and repurchased $38 million in shares year-to-date.
Headline financials
Revenue & EPS history
Prestige Consumer · Revenue · Quarterly
$284M
Revenue by segment
Prestige Consumer · $286M total across 2 segments · Q2 2024
- North American OTC Healthcare$244M-3.0%85.4%
- International OTC Healthcare$41.9M+12.6%14.6%
Forward guidance
Prestige Consumer Healthcare reaffirmed its fiscal year 2025 outlook for sales, adjusted earnings, and cash flow, expecting adjusted EPS to be at the higher end of the outlook.
Tailwinds
- Diverse portfolio of brands
- Second half revenue growth building on first half momentum in the international segment
- Continued improvements for the Women’s Health category
- Disciplined capital allocation
- Strong free cash flows enabling lower interest expense and shares outstanding
Headwinds
- Continued supply constraints for Clear Eyes
- Declines in the Cough & Cold category
- Declines in the Analgesic categories
- Revenue performance versus the prior year comparable period reflected anticipated limited ability to supply strong demand for Clear Eyes
- Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
+1.3%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+1.3%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+25.7%
Q4 2018
Best reaction
-14.3%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.5% | -7.4% | -4.9% | |
| Q3 2026 | -2.2% | -1.4% | +0.2% | |
| Q2 2026 | +2.2% | +1.3% | +1.7% | |
| Q4 2025 | +7.0% | +6.8% | +4.5% | |
| Q3 2025 | +14.8% | +13.0% | +17.0% | |
| Q2 2025 | +3.5% | +5.1% | +8.6% | |
| Q1 2025 | -2.4% | -0.9% | +9.5% | |
| Q4 2024 | -5.7% | -8.3% | -8.0% | |
| Q3 2024 | +9.2% | +5.8% | +17.2% | |
| Q2 2024 | +0.1% | +0.6% | -1.5% | |
| Q1 2024 | +2.2% | -2.5% | -11.4% | |
| Q4 2023 | -0.8% | -4.7% | -4.5% | |
| Q3 2023 | -7.9% | -8.3% | -8.9% | |
| Q2 2023 | +2.2% | +4.6% | +17.7% | |
| Q1 2023 | -0.3% | -3.9% | -15.2% | |
| Q4 2022 | -0.8% | +4.0% | +1.6% | |
| Q3 2022 | -0.2% | +2.2% | +1.1% | |
| Q2 2022 | +2.5% | +1.9% | -6.0% | |
| Q1 2022 | +10.5% | +12.3% | +8.1% | |
| Q4 2021 | +4.0% | +6.2% | +12.8% | |
| Q3 2021 | +3.2% | +5.5% | +6.3% | |
| Q2 2021 | -3.5% | +3.0% | +6.9% | |
| Q1 2021 | +2.7% | -1.9% | -5.2% | |
| Q4 2020 | +1.7% | +0.1% | +3.5% | |
| Q3 2020 | +10.7% | +5.7% | -8.3% | |
| Q2 2020 | +5.8% | +8.5% | +8.2% | |
| Q1 2020 | -3.1% | -5.6% | -7.9% | |
| Q4 2019 | +3.8% | +1.1% | +0.5% | |
| Q3 2019 | -2.9% | +2.8% | -4.1% | |
| Q2 2019 | +4.3% | +12.2% | +7.4% | |
| Q1 2019 | +3.5% | +5.3% | +9.3% | |
| Q4 2018 | +25.7% | +21.4% | +25.1% | |
| Q3 2018 | -14.3% | -10.9% | -15.3% | |
| Q2 2018 | -8.3% | -9.3% | -4.9% | |
| Q1 2018 | +1.6% | +0.7% | -2.4% | |
| Q4 2017 | -8.3% | -11.2% | -9.5% | |
| Q3 2017 | +5.8% | +4.9% | +7.8% | |
| Q2 2017 | -0.5% | +0.8% | +0.6% | |
| Q1 2017 | -1.6% | -5.0% | -8.1% | |
| Q4 2016 | -0.7% | — | — | |
| Q3 2016 | +7.6% | — | — | |
| Q2 2016 | -1.7% | — | — | |
| Q1 2016 | -0.2% | — | — | |
| Q4 2015 | +3.3% | — | — | |
| Q3 2015 | +12.5% | — | — | |
| Q2 2015 | -7.6% | — | — | |
| Q1 2015 | +10.1% | — | — | |
| Q4 2014 | +0.2% | — | — | |
| Q3 2014 | -5.5% | — | — | |
| Q2 2014 | +13.2% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | -0.4% | — | — | |
| Q3 2013 | +5.8% | — | — | |
| Q2 2013 | +19.9% | — | — | |
| Q1 2013 | +4.1% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q3 2012 | -1.0% | — | — | |
| Q3 2011 | -1.0% | — | — | |
| Q2 2011 | -4.8% | — | — | |
| Q2 2012 | -4.8% | — | — | |
| Q4 2011 | -13.0% | — | — | |
| Q1 2011 | -13.0% | — | — | |
| Q1 2012 | -13.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro